TScan Therapeutics (NASDAQ:TCRX) Lowered to “Hold” at Zacks Investment Research

TScan Therapeutics (NASDAQ:TCRXGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company’s lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass. “

Separately, HC Wainwright dropped their price target on TScan Therapeutics from $21.00 to $15.00 in a research report on Tuesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $16.35.

TScan Therapeutics stock opened at $2.10 on Friday. TScan Therapeutics has a one year low of $1.60 and a one year high of $14.71. The business has a fifty day moving average of $2.81 and a two-hundred day moving average of $4.90.

In related news, CFO Brian M. Silver acquired 15,000 shares of the company’s stock in a transaction that occurred on Thursday, March 24th. The stock was purchased at an average price of $3.40 per share, for a total transaction of $51,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this link.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in TScan Therapeutics by 1.4% in the 1st quarter. BlackRock Inc. now owns 1,519,188 shares of the company’s stock valued at $4,254,000 after buying an additional 20,650 shares during the period. RA Capital Management L.P. purchased a new stake in TScan Therapeutics in the 3rd quarter valued at about $10,469,000. Deer Management Co. LLC acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at about $5,605,000. DC Funds LP acquired a new position in shares of TScan Therapeutics in the 3rd quarter valued at about $5,254,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of TScan Therapeutics by 10.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 550,000 shares of the company’s stock valued at $2,475,000 after purchasing an additional 53,417 shares in the last quarter. Institutional investors own 36.97% of the company’s stock.

About TScan Therapeutics (Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.

See Also

Get a free copy of the Zacks research report on TScan Therapeutics (TCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.